Automated Glory: $BNGO Rises +5.10% with Trader Robot Precision
In the ever-evolving landscape of active trading, AI-driven robots have become key players, providing insights and executing trades with precision. In this article, we delve into the recent performance of AI trading bots, particularly those accessible at "Day Trader: Medium Volatility Stocks for Active Trading (TA&FA)," which demonstrated their prowess by generating a notable +5.10% gain while trading BNGO over the past week.
BNGO's RSI Indicator Signals Transition
One crucial aspect of BNGO's recent trading activity is the Relative Strength Index (RSI) oscillator, which moved out of the overbought zone on December 29, 2023. This shift suggests a potential reversal from an upward trend to a downward one. Tickeron's A.I.dvisor, in analyzing similar instances, found that in 19 out of 20 cases where the RSI moved out of the overbought zone, the stock experienced a subsequent decline. This statistical observation gives traders a 90% likelihood of a downward move, prompting considerations for selling the stock or exploring put options.
Earnings Snapshot and Market Capitalization
Examining the last earnings report on November 09 reveals a notable -100 cents earnings per share, missing the estimated -97 cents. With 1.74 million shares outstanding, BNGO's current market capitalization stands at 59.43 million. It's crucial to note that this performance places BNGO within the Medical Specialties Industry, where the average market capitalization is 6.46 billion. Comparatively, BNGO's market cap appears significantly smaller, highlighting its distinct position within the industry.
Market Cap Comparisons
The Medical Specialties Industry presents a diverse range of market capitalizations, from 27 million to a staggering 3.82 trillion. Noteworthy companies in this sector include MKYSF with the highest valuation at 3.82 trillion and FOGCF at the lower end with a valuation of 27 million. BNGO's market cap, situated at 59.43 million, positions it within the mid-range of this industry spectrum.
Price Movements in the Industry
Understanding the broader market trends in the Medical Specialties Industry is essential. On average, weekly price growth for these stocks remained at 0%, while monthly growth registered at 11%, and quarterly growth at -6%. Within this spectrum, TIPS stood out with an impressive 286% price growth, while NMRD experienced a significant fall at -63%.
Volume Insights
Volume dynamics play a crucial role in understanding market activity. Across the Medical Specialties Industry, the average weekly volume growth was 127%, with monthly growth at 55%, and quarterly growth at 161%. These figures underscore the dynamic nature of trading within this sector and suggest heightened investor interest and participation.
The recent performance of AI trading bots, particularly in handling BNGO amidst changing market conditions, underscores the importance of adapting to evolving trends.
BNGO's Indicator enters downward trend
The Aroon Indicator for BNGO entered a downward trend on December 03, 2024. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 317 similar instances where the Aroon Indicator formed such a pattern. In of the 317 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on December 12, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on BNGO as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for BNGO turned negative on December 19, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNGO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where BNGO advanced for three days, in of 231 cases, the price rose further within the following month. The odds of a continued upward trend are .
BNGO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.597) is normal, around the industry mean (23.300). P/E Ratio (0.000) is within average values for comparable stocks, (83.485). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.993) is also within normal values, averaging (43.338).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. BNGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a developer of technologies for analysis of large biological molecules
Industry MedicalSpecialties